These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Development and characterization of amphotericin B bearing emulsomes for passive and active macrophage targeting. Gupta S; Vyas SP J Drug Target; 2007 Apr; 15(3):206-17. PubMed ID: 17454358 [TBL] [Abstract][Full Text] [Related]
29. Nanonization increases the antileishmanial efficacy of amphotericin B: an ex vivo approach. Manandhar KD; Yadav TP; Prajapati VK; Basukala O; Aganja RP; Dude A; Shrivastav ON; Sundar S Adv Exp Med Biol; 2014; 808():77-91. PubMed ID: 24595612 [TBL] [Abstract][Full Text] [Related]
30. In vitro evaluation of surface functionalized gelatin nanoparticles for macrophage targeting in the therapy of visceral leishmaniasis. Nahar M; Dubey V; Mishra D; Mishra PK; Dube A; Jain NK J Drug Target; 2010 Feb; 18(2):93-105. PubMed ID: 19640212 [TBL] [Abstract][Full Text] [Related]
32. Hemoglobin guided nanocarrier for specific delivery of amphotericin B to Leishmania infected macrophage. Bose PP; Kumar P; Dwivedi MK Acta Trop; 2016 Jun; 158():148-159. PubMed ID: 26945483 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis. Corral MJ; Serrano DR; Moreno I; Torrado JJ; Domínguez M; Alunda JM J Antimicrob Chemother; 2014 Dec; 69(12):3268-74. PubMed ID: 25096077 [TBL] [Abstract][Full Text] [Related]
34. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment. Bagre AP; Jain K; Jain NK Int J Pharm; 2013 Nov; 456(1):31-40. PubMed ID: 23994363 [TBL] [Abstract][Full Text] [Related]